吡柔比星膀胱灌注预防膀胱癌术后复发疗效观察

Clinical study on intravesical instillation of pirarubicin for preventing postoperative recurrence of superficial bladder cancer

目的探讨吡柔比星膀胱内灌注预防浅表性膀胱癌术后复发的临床疗效。方法89例浅表性膀胱癌患者于手术后1周内开始行吡柔比星膀胱灌注,每次30mg,每周1次,共8次,以后每月1次,连用10个月,总疗程12个月。结果术后平均随访时间(13.4±4.3)个月。肿瘤复发15例,复发率为16.8%。结论吡柔比星膀胱灌注预防浅表性膀胱癌术后复发效果明确,疗效满意,患者耐受性好,是较理想的膀胱灌注化疗药物。

Objective To investigate the efficacy of intravesical instillation of pirarubicin（THP） in preventing postoperative recurrence of superficial bladder cancer. Methods Eighty-nine patients with superficial bladder carcinoma received instillation of THP 30 mg intravesically which was retained for 30 minutes in bladder after TUR-Bt or partial cystectomy once a week for 8 weeks, and then once a month for 10 months. Results All the patients were followed-up for an average time of （ 13.4 ± 4. 3） months. Tumor recurrence was found in 15 cases and the total recurrence rate was 16. 8%. Urinary irritation and abnormal urine analysis were the predominant adverse reactions. Condusion Intravesical administration of THP after operation was effective and well-tolerated for preventing tumor recurrence.